We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UTHR vs. NBIX: Which Stock Is the Better Value Option?
Read MoreHide Full Article
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR - Free Report) and Neurocrine Biosciences (NBIX - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
United Therapeutics has a Zacks Rank of #1 (Strong Buy), while Neurocrine Biosciences has a Zacks Rank of #2 (Buy) right now. This means that UTHR's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
UTHR currently has a forward P/E ratio of 8.81, while NBIX has a forward P/E of 745.79. We also note that UTHR has a PEG ratio of 29.37. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NBIX currently has a PEG ratio of 35.51.
Another notable valuation metric for UTHR is its P/B ratio of 2.12. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, NBIX has a P/B of 27.47.
These metrics, and several others, help UTHR earn a Value grade of B, while NBIX has been given a Value grade of F.
UTHR stands above NBIX thanks to its solid earnings outlook, and based on these valuation figures, we also feel that UTHR is the superior value option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
UTHR vs. NBIX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR - Free Report) and Neurocrine Biosciences (NBIX - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
United Therapeutics has a Zacks Rank of #1 (Strong Buy), while Neurocrine Biosciences has a Zacks Rank of #2 (Buy) right now. This means that UTHR's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
UTHR currently has a forward P/E ratio of 8.81, while NBIX has a forward P/E of 745.79. We also note that UTHR has a PEG ratio of 29.37. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NBIX currently has a PEG ratio of 35.51.
Another notable valuation metric for UTHR is its P/B ratio of 2.12. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, NBIX has a P/B of 27.47.
These metrics, and several others, help UTHR earn a Value grade of B, while NBIX has been given a Value grade of F.
UTHR stands above NBIX thanks to its solid earnings outlook, and based on these valuation figures, we also feel that UTHR is the superior value option right now.